Company intelligence / Profile preview
Avalo Therapeutics
Rockville, Maryland, United Statesannualreports.com ↗
- Ownership
- Public · AVTX
- Employees
- ~23
- Development stage
- Phase 2
01
Overview
Avalo’s lead program is AVTX-009, an anti–IL‑1β monoclonal antibody in Phase 2 for hidradenitis suppurativa. The company recently pivoted its pipeline to focus on this asset after acquiring AlmataBio and deprioritizing previous assets such as quisovalimab and a BTLA agonist fusion protein. Previous programs included AVTX‑002 for non-eosinophilic asthma and COVID‑19 ARDS; however, recent trials did not meet primary endpoints but showed positive trends in biomarker-defined subpopulations[10][7]. The company has secured significant funding to advance the current lead program through key clinical milestones.
- Therapeutic areas
- PulmonologyImmunologyDermatologyRare DiseasesInfectious Diseases
- Modalities
- monoclonal antibodies (mAbs)fusion proteins
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
No major pharmaceutical partnerships disclosed post-pipeline pivot. Recent investors include Commodore Capital, TCGX, BVF Partners, Deep Track Capital, OrbiMed, Petrichor and RA Capital Management[7].
Beyond the preview
Go deeper on Avalo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avalo Therapeutics.